A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Abstract Text:

Kn Roy Chengappa,David J Kupfer,Haranath Parepally,Vineeth John,Ranita Basu,Joan Buttenfield,Patricia Schlicht,Patricia Houck,Jaspreet S Brar,Samuel Gershon,Kn Roy Chengappa,David J Kupfer,Haranath Parepally,Vineeth John,Ranita Basu,Joan Buttenfield,Patricia Schlicht,Patricia Houck,Jaspreet S Brar,Samuel Gershon,

OBJECTIVES: This pilot study evaluated the efficacy and safety of adjunctive topiramate compared with placebo in the treatment of patients with a diagnosis of schizoaffective disorder, bipolar type (SAD-BT). METHODS: A sample of 48 adult patients with a Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) diagnosis of SAD-BT (supported by the Structured Clinical Interview for DSM-IV Axis I Disorder, Patient Edition) were randomly assigned in a 2:1 ratio (favoring topiramate) to 8 weeks of double-blind treatment with topiramate (100-400 mg/day) or placebo. Patients who had achieved a > or =20% decrease from baseline in their Positive and Negative Syndrome Scale (PANSS) total scores were given the opportunity to continue for an additional 8 weeks of double-blind treatment. The dosage of the study medicine was continued unchanged from the earlier 8-week study period. At the end of the study period, the study medicine was tapered and discontinued over a 2-week period. Primary efficacy was assessed at 8 weeks using the mean change between treatment groups of the PANSS total scores in the intent-to-treat population of randomized patients. Several secondary measures were also assessed. Safety analyses included monitoring of adverse events, vital signs, electrocardiogram (ECG) and laboratory values. RESULTS: Even though both treatments reduced scores on various psychopathology rating scales, adjunctive topiramate treatment (nearly 275 mg/day) did not show increased efficacy relative to placebo on the primary outcome measure (PANSS scale) or any of the secondary outcome measures. Topiramate-treated patients lost significantly more body weight than placebo-treated patients, which led to a significant reduction in body mass index (BMI). Relative to adjunctive placebo, topiramate-treated patients experienced higher rates of paresthesia, sedation, word-finding difficulty, sleepiness, and forgetfulness, but these differences were not statistically significant. There were no clinically significant abnormalities in either the ECG or laboratory results. There were no serious adverse events in the study. Further, there was no worsening of the PANSS total scores (to > or =10% from baseline), and no significant differences between the treatments on worsening of total Montgomery-Asberg Depression Rating Scale (MADRS) scores [1/13 (7.7%) for placebo; 1/25 (4.0%) for topiramate]. CONCLUSIONS: This pilot study did not support clinical efficacy for adjunctive topiramate treatment in patients with SAD-BT. There were no major safety or tolerability issues in this study. Confirming the results of other studies, topiramate-treated patients did experience greater body weight loss and reduction in BMI.

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Publishing Authors By Initials

K Roy Chengappa,DJ Kupfer,H Parepally,V John,R Basu,J Buttenfield,P Schlicht,P Houck,JS Brar,S Gershon,K Roy Chengappa,DJ Kupfer,H Parepally,V John,R Basu,J Buttenfield,P Schlicht,P Houck,JS Brar,S Gershon,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Bipolar disorders

VOLUME: 9

Page Numbers: 609-17

Journal Abbreviation: Bipolar Disord

ISSN: 1398-5647

DAY: 11

MONTH: Sep

YEAR: 2007

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 100883596

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.

AFFILIATION: Western Psychiatric Institute and Clinic, School of Medicine, University of Pittsburgh, and Mayview State Hospital, Pittsburgh, PA, USA. chengappakn@upmc.edu

Country: Denmark

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Bipolar Disord

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type Related Publications

• A METHOD FOR STUDYING INTRACELLULAR MOVEMENT OF WATER-SOLUBLE ISOTOPES PRIOR TO RADIOAUTOGRAPHY.
• A placebo-controlled, random-assignment, parallel-group pilot study of adjunctive topiramate for patients with schizoaffective disorder, bipolar type.
• A role for suppressor T cells in immunological enhancement of tumor growth.
• Age-related trend for osteopenia in femurs of female C57BL/6 mice.
• Aging and cortisol resistance to suppression by dexamethasone: a positive correlation.
• Analytical AIDS.
• Antipsychotics in the elderly.
• Behavioral, physiological, and neuroendocrine responses to arecoline in normal twins and "well state" bipolar patients.
• Bone morphogenetic protein-2 and -4 limit the number of enteric neurons but promote development of a TrkC-expressing neurotrophin-3-dependent subset.
• Cholesterol dependence of varicella-zoster virion entry into target cells.
• DNA sequence variability in Oka vaccine isolates.
• Gangliogenesis in the enteric nervous system: roles of the polysialylation of the neural cell adhesion molecule and its regulation by bone morphogenetic protein-4.
• Hand2 is necessary for terminal differentiation of enteric neurons from crest-derived precursors but not for their migration into the gut or for formation of glia.
• Innervation and regulation of the pancreas by neurons in the gut.
• Intravenous GABA administration is anxiogenic in man.
• Lithium in children of lithium-responding parents.
• Methylphenidate infusion in euthymic bipolars: effect of carbamazepine pretreatment.
• Monoamine oxidase type A in fibroblasts from patients with bipolar depressive illness.
• Mycobacterium avium intracellulare infection in children with AIDS.
• No association of trace amine receptor genes with bipolar disorder.
• Nurse work environments and occupational safety in intensive care units.
• Platelet 3H-imipramine binding in euthymic bipolar patients.
• Platelet vasopressin receptors in bipolar affective illness.
• Reaction time as a diagnostic measure in senility.
• Relationship of HLA to major affective disorder not supported.
• Safety data on zimelidine hydrochloride following an overdose.
• Saltatory forward movement of a poly(A) polymerase during poly(A) tail addition.
• Serotonergic neurotransmission in the gut.
• Transplanting the enteric nervous system: a step closer to treatment for aganglionosis.
• Varicella-zoster virus infections.